Software Daily Summary
Software Daily Summary: What Happened on October 26, 2026
Lunit and Summit to assess AI pathology platform in ivonescimab research
The planned analysis will look for biomarkers and group patients, but the agreement excludes clinical outcome data.
Today in brief
Lunit and Summit plan to use AI analysis of tumor slides to study biomarkers and patient groups in ivonescimab research.1
Also published
- AI Twins Are Growing in the Pharma Industry Pharmaceutical Executive